Efficacy of intravenous vs intraperitoneal lidocaine for postoperative analgesia in laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled trial

Comparing the efficacy of perioperative intravenous infusion versus intraperitoneal instillation of local anesthetic in reducing post-operative opioid consumption in laparoscopic cholecystectomy: a randomized double-blind controlled trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20190316001

Enrollment

162

Registered

2019-03-16

Start date

2019-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total opioid consumption in patients receiving lidocaine IV or IP vs saline in laparoschopic surgery Incidence of shoulder pain Time discharge criteria met

Interventions

The patient in this group receives intravenous saline and intraperitoneal saline,Group IV lidocaine will be given an intravenous bolus dose of 1.5 mg/kg 2% lidocaine without epinephrine immediately a

Placebo Comparator Drug,Active Comparator Drug,Active Comparator Drug

Control,IV lidocaine,IP lidocaine

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: - All genders between 18 to 70 years of age with good conscious - Patients with American Society of Anesthesiologists (ASA) physical status classification of I-II - Patients subjected to elective laparoscopic cholecystectomy - Patients who have given informed consent to participate in this study

Exclusion criteria

Exclusion criteria: Exclusion criteria: - Patients with BMI >35 (morbid obesity) - Patients with suspected CA gallbladder and acute cholecystitis -Patients with severe obstructive sleep apnea -Patients with preexisting chronic pain, including those who are currently receiving opioid treatments, and those who received analgesics 24 hours prior to surgery - Patients with a history of local anesthetic allergy -Patients with previous abdominal surgeries - Patients with severe liver, cardiac or renal disease (serum creatinine >2 mg/dl) - Patients who are unable to communicate and cooperate to pain assessment

Design outcomes

Primary

Measure	Time frame
Opioid consumption 0, 2, 4, 6, 12, 24 hours Visual analogue scale	—

Secondary

Measure	Time frame
Recovery time at 24 hours Discharge criteria,Side effects Through out Signs and symptoms	—

Countries

Thailand

Contacts

Public ContactAtipa Nitayamekin

Chiang Mai University

atipa.nita@gmail.com0846117922

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026